Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 995 across all filing types
Latest filing 2018-11-25 Call Transcript
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
ANMI Transaction - Investor Conference Call Details 2 pages 201.1KB
Call Transcript Classification · 90% confidence The document is an announcement of a conference call related to the acquisition of Advanced Nuclear Medicine Ingredients (ANMI) SA by Telix Pharmaceuticals. It provides details about the call, including date, time, dial-in numbers, and registration links. There is no substantive financial data, detailed financial results, or management discussion of financial performance. The document is not a transcript of the call but an invitation and announcement for the call. It is also not a full report or regulatory filing but an update on a capital transaction event with an associated investor call. Therefore, the most appropriate classification is a Call Transcript (CT) category, as it relates to a conference call about a transaction. However, since this is only an announcement of the call and not the transcript itself, the best fit is the Call Transcript (CT) category because the content is focused on the call event related to the transaction. Confidence is high given the clear context and content.
2018-11-25 English
Appendix 4C - September Quarter 7 pages 556.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Cashflow Statement: September 2018 Quarter' and includes detailed financial data such as cash flows from operating, investing, and financing activities for the quarter and year to date. It references compliance with Listing Rule 4.7B and includes a signed compliance statement. The document contains substantive financial data and analysis for a period shorter than a full fiscal year, specifically a quarter. It is not merely an announcement or a certification but a full quarterly financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2018
2018-10-30 English
Quarterly Program Update 9 pages 1.4MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Q3 Program Update' and dated October 2018, indicating it is a quarterly update. It contains detailed information about clinical trials progress, manufacturing and distribution partnerships, pipeline overview, and upcoming catalysts/events. The content includes substantive operational and clinical progress data rather than just high-level financial results or announcements. There are no indications that this is a full annual report or an earnings release with summarized financial highlights only. The document is not a transcript, regulatory filing, or announcement of a report publication. Given the detailed program update nature and the quarterly timing, this fits best as an Interim / Quarterly Report (IR). The document length (7,885 characters) supports it being a substantive report rather than a brief announcement. Q3 2018
2018-10-30 English
Telix Commences ZIRCON Phase III Renal Cancer Imaging Trial 2 pages 215.6KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the commencement of a Phase III clinical trial (ZIRCON) by Telix Pharmaceuticals. It provides details about the trial, the drug TLX250, the market opportunity, and company background. There are no financial statements, regulatory filings, voting results, or management changes. The content is focused on clinical trial initiation and company product development, typical of a Capital/Financing Update or general corporate announcement. However, since it does not discuss fundraising, capital structure changes, or financing activities explicitly, it does not fit the Capital/Financing Update (CAP) category. It is also not a regulatory filing or report publication announcement. Given the nature of the announcement about a clinical trial commencement, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about clinical trial progress and company operations. Confidence is high due to clear content and absence of financial or governance report elements.
2018-10-22 English
Telix Receives Approval to Commence Glioblastoma Trial 2 pages 167.2KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Telix Pharmaceuticals has received regulatory approval to commence a clinical trial for a glioblastoma treatment. It contains no financial data, no detailed financial performance, no management discussion of financial results, no voting results, no share transactions, no legal proceedings, and no regulatory certifications. The document is short (4380 characters) and primarily serves as a corporate announcement about a clinical trial approval. It does not fit into any financial report or regulatory filing categories such as Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not a report publication announcement since it does not mention any report being published or attached. The content is best classified as a general regulatory announcement or corporate update that does not fit other categories, thus falling under Regulatory Filings (RNS) as a fallback category.
2018-10-17 English
RTM to Manufacture Kidney Imaging Program in Europe 2 pages 188.6KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing a manufacturing agreement between Telix Pharmaceuticals and Radboud Translational Medicine B.V. It discusses the partnership, process development, and production plans for a kidney imaging program in Europe. There is no financial data, regulatory filing, voting results, or report publication mentioned. The content is primarily a corporate announcement about a manufacturing and clinical trial collaboration, not a financial report, regulatory filing, or shareholder communication. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate update, which corresponds to Regulatory Filings (RNS). The document length is 4274 characters, which is relatively short and consistent with an announcement rather than a detailed report.
2018-10-16 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.